Park Avenue Securities LLC Acquires Shares of 1,999 Charles River Laboratories International, Inc. $CRL

Park Avenue Securities LLC acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,999 shares of the medical research company’s stock, valued at approximately $303,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Rothschild Investment LLC raised its holdings in shares of Charles River Laboratories International by 480.0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after buying an additional 144 shares during the period. Brooklyn Investment Group raised its holdings in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after buying an additional 86 shares during the period. HM Payson & Co. purchased a new stake in shares of Charles River Laboratories International in the first quarter worth approximately $31,000. Family Legacy Financial Solutions LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter worth approximately $71,000. Finally, Parallel Advisors LLC raised its holdings in shares of Charles River Laboratories International by 83.7% in the first quarter. Parallel Advisors LLC now owns 474 shares of the medical research company’s stock worth $71,000 after buying an additional 216 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Up 6.5%

Charles River Laboratories International stock opened at $156.61 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock has a market capitalization of $7.71 billion, a price-to-earnings ratio of -117.75, a PEG ratio of 3.93 and a beta of 1.47. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The business has a fifty day moving average price of $159.46 and a 200-day moving average price of $147.31.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the firm earned $2.80 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CRL shares. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price target for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Citigroup upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Barclays raised their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an “equal weight” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Finally, Evercore ISI raised their price objective on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Six research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average target price of $177.07.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).